KZIA
Closed
Kazia Therapeutics Ltd Adr
6.63
+0.36 (+5.74%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.27
Day's Range: 6.01 - 6.645
Send
sign up or login to leave a comment!
When Written:
1.13
Kazia Therapeutics Ltd is a biotechnology company based in Australia that focuses on the development of innovative cancer therapies. The company's lead product candidate, GDC-0084, is a brain-penetrant small molecule inhibitor of the PI3K/Akt/mTOR pathway, which is being developed for the treatment of glioblastoma multiforme, the most common and aggressive form of primary brain cancer. Kazia Therapeutics also has a preclinical pipeline of potential cancer therapies, including KZ-321, a novel small molecule inhibitor of the DCLK1 kinase, which is being developed for the treatment of colorectal cancer. The company's American Depositary Receipts (ADRs) trade on the NASDAQ exchange under the ticker symbol "KZIA."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








